SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-007567
Filing Date
2022-05-05
Accepted
2022-05-05 07:40:55
Documents
14
Period of Report
2022-05-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ntla-20220505.htm   iXBRL 8-K 56795
2 EX-99.1 ntla-ex99_1.htm EX-99.1 190267
3 GRAPHIC img149557450_0.jpg GRAPHIC 12257
  Complete submission text file 0000950170-22-007567.txt   399354

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ntla-20220505.xsd EX-101.SCH 2481
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ntla-20220505_pre.xml EX-101.PRE 9896
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ntla-20220505_lab.xml EX-101.LAB 13466
8 EXTRACTED XBRL INSTANCE DOCUMENT ntla-20220505_htm.xml XML 4763
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 22894114
SIC: 2835 In Vitro & In Vivo Diagnostic Substances